Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF
Author(s)
Type
Journal Article
Date Issued
2015-07-31
Date Acceptance
2015-06-25
Citation
European Heart Journal, 2015, 36 (38), pp.2576-2584
ISSN
1522-9645
Publisher
Oxford University Press
Start Page
2576
End Page
2584
Journal / Book Title
European Heart Journal
Volume
36
Issue
38
Copyright Statement
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
License URL
Subjects
Science & Technology
Life Sciences & Biomedicine
Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology
Heart failure
Neprilysin
Receptors
Angiotensin
Age
SYSTOLIC HEART-FAILURE
CLINICAL-TRIALS
NEPRILYSIN INHIBITION
ENALAPRIL
COMORBIDITIES
MANAGEMENT
MORTALITY
PROGRAM
RISK
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Aminobutyrates
Angiotensin Receptor Antagonists
Cause of Death
Heart Failure
Humans
Middle Aged
Tetrazoles
Treatment Outcome
Young Adult
PARADIGM-HF Investigators and Committees
Cardiovascular System & Hematology
1102 Cardiovascular Medicine And Haematology
Publication Status
Published